ST Nation: The phase II and III clinical trials of Shishanjianjia controlled release tablets have been completed with 200 subjects enrolled.

Announcement from ST Bank: ST Wanhong Pharmaceutical Group Co., Ltd., a wholly-owned subsidiary, has completed the enrollment of 200 subjects for the Phase II/III pivotal registration clinical trial of its new Class 2.2 drug, Shen Shan alkaloid methyl controlled release tablets, for the treatment of mild to moderate Alzheimer's disease dementia.